145 related articles for article (PubMed ID: 8594281)
1. Evaluation of serum prostate-specific antigen levels after postoperative radiation therapy for pathologic stage T3, N0 prostate cancer.
Buskirk SJ; Schild SE; Durr ED; Robinow JS; Bock FF; Wolfe JT; Tomera KM; Ferrigni RG
Mayo Clin Proc; 1996 Mar; 71(3):242-8. PubMed ID: 8594281
[TBL] [Abstract][Full Text] [Related]
2. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
[TBL] [Abstract][Full Text] [Related]
3. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
4. Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer.
Valicenti RK; Gomella LG; Ismail M; Mulholland SG; Petersen RO; Corn BW
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):501-6. PubMed ID: 9806507
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy.
Schild SE; Wong WW; Grado GL; Buskirk SJ; Robinow JS; Frick LM; Ferrigni RG
Mayo Clin Proc; 1994 Jul; 69(7):613-9. PubMed ID: 7516988
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
7. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy.
Schild SE; Buskirk SJ; Wong WW; Halyard MY; Swanson SK; Novicki DE; Ferrigni RG
J Urol; 1996 Nov; 156(5):1725-9. PubMed ID: 8863580
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy.
Goluboff ET; Heitjan DF; DeVries GM; Katz AE; Benson MC; Olsson CA
J Urol; 1997 Nov; 158(5):1876-8; discussion 1878-9. PubMed ID: 9334621
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
10. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
11. Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate.
Petrovich Z; Lieskovsky G; Langholz B; Formenti S; Baert L; Streeter O; Skinner DG
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):139-47. PubMed ID: 9422570
[TBL] [Abstract][Full Text] [Related]
12. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up.
Medini E; Medini I; Reddy PK; Levitt SH
Cancer; 1996 Sep; 78(6):1254-9. PubMed ID: 8826948
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant and salvage radiotherapy after radical prostatectomy.
Höcht S; Wiegel T; Schostak M; Hinkelbein W
Onkologie; 2002 Jun; 25(3):201-6. PubMed ID: 12119453
[TBL] [Abstract][Full Text] [Related]
14. Radiation therapy for increasing prostate-specific antigen levels after radical prostatectomy.
Perez CA; Michalski JM; Baglan K; Andriole G; Cui Q; Lockett MA
Clin Prostate Cancer; 2003 Mar; 1(4):235-41. PubMed ID: 15040882
[TBL] [Abstract][Full Text] [Related]
15. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
[TBL] [Abstract][Full Text] [Related]
16. Treatment results of adjuvant radiotherapy and salvage radiotherapy after radical prostatectomy for prostate cancer.
Wadasaki K; Kaneyasu Y; Kenjo M; Matsuura K; Murakami Y; Hashimoto Y; Ito K; Kiriu H; Ito A
Int J Clin Oncol; 2007 Feb; 12(1):37-41. PubMed ID: 17380439
[TBL] [Abstract][Full Text] [Related]
17. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
Zagars GK; Pollack A
Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
Tiguert R; Rigaud J; Lacombe L; Laverdière J; Fradet Y
J Urol; 2003 Aug; 170(2 Pt 1):447-50. PubMed ID: 12853796
[TBL] [Abstract][Full Text] [Related]
19. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
20. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
